QRX003 Lotion for Netherton Syndrome
Part of Genetic & congenital, Skin clinical trials.
This study tests a new lotion (QRX003) designed to treat Netherton Syndrome, a rare genetic skin condition. The lotion is applied to affected skin areas to see if it can reduce symptoms and improve skin health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 4 years old
- You have a confirmed genetic diagnosis of Netherton Syndrome
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
- You have no active cancer, uncontrolled diabetes, or serious infections
- You have not used certain skin treatments (steroids, retinoids, UV therapy) in the treatment area within recent weeks
- You are not enrolled in any other experimental treatment studies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BCX17725 in people with Netherton syndrome to see if it is safe and how the body handles it. It may help by reducing skin symptoms like redness and scaling.
This trial tests a lotion called QRX003 for Netherton syndrome, a rare skin condition. It aims to see if the lotion is safe and helpful for managing symptoms.
This trial tests a prescription lotion (QRX003) to see if it is safe and helpful for people with Netherton syndrome. Because the study checks skin symptoms on certain body areas and closely controls other treatments, it may be best for patients who can keep their current regimen stable.
This study looks at the bacteria on the skin and in the gut of people with Netherton syndrome, a condition that affects the skin barrier and often causes allergies. It also compares these findings to healthy volunteers to understand how the microbiome might be different.
This study looks at “skin and blood biomarkers,” meaning measurable signs in the body, in people with ichthyosis to better understand the condition. It may help researchers find ways to track disease activity and evaluate future treatments.
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
Hear when a new Netherton Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.